$44.02
1.272.97%
Last update: Nov 10, 4:00 AM
Boston Scientific Corp
BSXNYSE
Boston Scientific fell 56.4% from $100.91 to $44.02, behind the S&P 500's +10.5%. Its worst day was Feb 4 (−17.6%), and its low came Oct 7 at $41.58.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Boston Scientific closed at its highest level of the year, 4.0% above where the year started.
+0.8% · S&P 500 −1.7%
EPS of $0.80 beat the $0.78 estimate on $5.3B revenue (est. $5.3B); Q1 revenue guidance of $5.1B–$5.2B against the $5.2B consensus.
Story events cover the past 12 months · Times ET
−17.6%, the year's worst day, on 78M shares, the year's heaviest volume · S&P 500 −0.5%
Raymond James moved Boston Scientific from Strong Buy to Outperform and cut its price target from $97.00 to $88.00; shares fell 9.0%.
−9.0% · S&P 500 −0.3%
EPS of $0.80 beat the $0.79 estimate on $5.2B revenue (est. $5.2B); Q2 revenue guidance of $5.3B–$5.4B against the $5.6B consensus.
+9.0%, the year's best day · S&P 500 +1.0%
Boston Scientific shares fell 12.5%, while the S&P 500 fell 0.0%.
−12.5% · S&P 500 0.0%
EPS of $0.86 beat the $0.83 estimate on $5.4B revenue (est. $5.4B); Q3 revenue guidance of $5.2B–$5.3B against the $5.4B consensus.
0.0% · S&P 500 −1.5%
Boston Scientific closed at its lowest level of the year, 58.8% below where the year started.
−1.4% · S&P 500 −0.2%
EPS of $0.73 beat the $0.73 estimate on $5.1B revenue (est. $5.1B); FY revenue guidance of $20.9B against the $21.1B consensus.
−5.8% · S&P 500 +0.3%
Where it ended: a close of $44.02 on Nov 9, 2026. Up next: Q4 2026 earnings on Feb 3, 2027 (EPS est. $0.78, revenue est. $5.2B).
Nothing in the past 12 months.
All BSX dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for BSX and SPY from Benzinga historical bars. Not investment advice.
